- Home
- QTRX vs FHTX Comparison
QTRX vs FHTX Comparison
Compare QTRX & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTRX
- FHTX
- Stock Information
- Founded
- QTRX 2007
- FHTX 2015
- Country
- QTRX United States
- FHTX United States
- Employees
- QTRX N/A
- FHTX N/A
- Industry
- QTRX Biotechnology: Laboratory Analytical Instruments
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- QTRX Industrials
- FHTX Health Care
- Exchange
- QTRX Nasdaq
- FHTX Nasdaq
- Market Cap
- QTRX 439.1M
- FHTX 513.7M
- IPO Year
- QTRX 2017
- FHTX 2020
- Fundamental
- Price
- QTRX $10.50
- FHTX $5.14
- Analyst Decision
- QTRX Strong Buy
- FHTX Strong Buy
- Analyst Count
- QTRX 4
- FHTX 5
- Target Price
- QTRX $23.25
- FHTX $13.80
- AVG Volume (30 Days)
- QTRX 375.4K
- FHTX 197.3K
- Earning Date
- QTRX 11-12-2024
- FHTX 11-04-2024
- Dividend Yield
- QTRX N/A
- FHTX N/A
- EPS Growth
- QTRX N/A
- FHTX N/A
- EPS
- QTRX N/A
- FHTX N/A
- Revenue
- QTRX $129,330,000.00
- FHTX $25,515,000.00
- Revenue This Year
- QTRX $13.89
- FHTX N/A
- Revenue Next Year
- QTRX $15.51
- FHTX $11.54
- P/E Ratio
- QTRX N/A
- FHTX N/A
- Revenue Growth
- QTRX 15.52
- FHTX N/A
- 52 Week Low
- QTRX $9.87
- FHTX $2.70
- 52 Week High
- QTRX $29.70
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- QTRX 40.42
- FHTX 27.35
- Support Level
- QTRX $10.29
- FHTX $4.69
- Resistance Level
- QTRX $11.51
- FHTX $5.70
- Average True Range (ATR)
- QTRX 0.80
- FHTX 0.61
- MACD
- QTRX -0.13
- FHTX -0.14
- Stochastic Oscillator
- QTRX 20.10
- FHTX 16.24
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory, Homebrew - Custom Assay Development, and Uman NF-Light.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.